These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Happy birthday neuroleptics! 50 years later: la folie du doute. Stip E Eur Psychiatry; 2002 May; 17(3):115-9. PubMed ID: 12052571 [TBL] [Abstract][Full Text] [Related]
23. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance. Wiesel FA Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610 [TBL] [Abstract][Full Text] [Related]
24. Dopamine receptors, neuroleptics, and schizophrenia. Snyder SH Am J Psychiatry; 1981 Apr; 138(4):460-4. PubMed ID: 6111227 [TBL] [Abstract][Full Text] [Related]
25. [Fritz Flügel (1897-1973). Early research on neuroleptics]. Bleich S; Breuer L; Kornhuber J Nervenarzt; 2006 Mar; 77(3):350-4. PubMed ID: 16437255 [TBL] [Abstract][Full Text] [Related]
26. History of the discovery and clinical introduction of chlorpromazine. López-Muñoz F; Alamo C; Cuenca E; Shen WW; Clervoy P; Rubio G Ann Clin Psychiatry; 2005; 17(3):113-35. PubMed ID: 16433053 [TBL] [Abstract][Full Text] [Related]
27. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Nagaoka S; Iwamoto N; Arai H Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412 [TBL] [Abstract][Full Text] [Related]
28. The effects of drugs on the processes regulating the functional activity of brain monoamines. Grahame-Smith DG Prog Neuropsychopharmacol; 1979; 3(1-3):15-23. PubMed ID: 45560 [TBL] [Abstract][Full Text] [Related]
29. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Brunello N; Masotto C; Steardo L; Markstein R; Racagni G Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893 [TBL] [Abstract][Full Text] [Related]
30. The complexity of the dopaminergic synapses and their modulation by antipsychotics. Leuner K; Müller WE Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891 [TBL] [Abstract][Full Text] [Related]
31. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. Reynolds GP; Rossor MN; Iversen LL J Neural Transm Suppl; 1983; 18():273-7. PubMed ID: 6135746 [TBL] [Abstract][Full Text] [Related]
32. Chapter 33: the history of movement disorders. Lanska DJ Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136 [TBL] [Abstract][Full Text] [Related]
33. The evolution of drug development in schizophrenia: past issues and future opportunities. Carpenter WT; Koenig JI Neuropsychopharmacology; 2008 Aug; 33(9):2061-79. PubMed ID: 18046305 [TBL] [Abstract][Full Text] [Related]
34. [Principles of chemotherapy of paranoid schizophrenia]. Vanelle JM; Loloum T Encephale; 1991; 17(4):235-40. PubMed ID: 1683623 [TBL] [Abstract][Full Text] [Related]
35. My father, my life, and chlorpromazine. Artigues MF N C Med J; 2000; 61(2):90-4. PubMed ID: 10737030 [No Abstract] [Full Text] [Related]
36. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Mignon L; Wolf WA Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404 [TBL] [Abstract][Full Text] [Related]
38. [Atypical neuroleptics. Review of the available clinical data]. Verhoeven WM; Den Boer JA Encephale; 1990; 16(6):439-44. PubMed ID: 1983216 [TBL] [Abstract][Full Text] [Related]
39. [Mechanism of molecular action of neuroleptics]. de Erausquin GA Vertex; 2003; 14(51):36-44. PubMed ID: 12690408 [TBL] [Abstract][Full Text] [Related]
40. Relationships among biochemical, clinical, and pharmacokinetic variables in neuroleptic-treated schizophrenic patients. Sedvall G Adv Biochem Psychopharmacol; 1980; 24():521-8. PubMed ID: 6105798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]